People: Pharmacyclics Inc (PCYC.O)

PCYC.O on Nasdaq

124.44USD
11:37am EDT
Price Change (% chg)

$0.50 (+0.40%)
Prev Close
$123.95
Open
$124.49
Day's High
$124.49
Day's Low
$124.49
Volume
180,865
Avg. Vol
1,063,015
52-wk High
$154.89
52-wk Low
$82.51

Search Stocks

Summary

Name Age Since Current Position

Robert Duggan

69 2009 Chairman of the Board, Chief Executive Officer

Manmeet Soni

36 2014 Chief Financial Officer, Executive Vice President - Finance, Chief Accounting Officer, Treasurer

Mahkam Zanganeh

43 2012 Chief Operating Officer

Rainer Erdtmann

50 2013 Senior Vice President - Investor Relations and Administration

Urte Gayko

42 2013 Senior Vice President - Regulatory

Sumita Ray

2013 Chief Compliance Officer, Associate General Counsel - Healthcare Law

Gregory Hemmi

47 2010 Vice President - Chemical Operations

Darrin Beaupre

2013 Vice President - Clinical Medicine and Early Development

Betty Chang

2013 Vice President - Research/Biology

Fong Clow

55 2012 Vice President - Biostatistics, Programming, and Data Management

Elizabeth Faust

48 2013 Vice President - Medical Affairs

Thorsten Graef

2013 Vice President - Clinical Science

Dana Lee

50 2013 Vice President - Clinical Drug Safety

Matthew Outten

40 2013 Vice President - Commercial Operations

Scott Shearer

48 2012 Vice President - Global Quality

Christophe Suchet

43 2013 Vice President - Information Technology

Richard Love

52 2013 General Counsel

Shawn Cline Tomasello

2014 Chief Commercial Officer

Maria Fardis

46 2013 Chief of Oncology Operations and Alliances

Jesse McGreivy

45 2013 Chief Medical Officer

Heow Tan

55 2013 Chief of Technical Operations

Robert Booth

60 2010 Independent Director

Kenneth Clark

55 2012 Independent Director

Eric Halvorson

2011 Independent Director

Minesh Mehta

56 2008 Independent Director

David Smith

43 2008 Independent Director

Richard Van den Broek

48 2009 Independent Director

Biographies

Name Description

Robert Duggan

Mr. Robert W. Duggan serves as Chairman of the Board, Chief Executive Officer of Pharmacyclics, Inc. He has been a member of Board since September 2007 and has served as Chief Executive Officer since September 2008. Mr. Duggan served as Chairman of the Board of Directors of Computer Motion, Inc., a computerized surgical systems company, from 1990 to 2003 and Chief Executive Officer from 1997. Computer Motion was acquired by Intuitive Surgical, Inc. in 2003. Mr. Duggan served on the Intuitive Surgical, Inc. Board from 2003 through March 2011. Mr. Duggan has been a private venture investor for more than 30 years and has participated as a director of, investor in, and advisor to numerous businesses in the medical equipment, computer local and wide area network, PC hardware and software distribution, digital encryption, consumer retail goods and outdoor media communication industries. Mr. Duggan has also assisted in corporate planning, capital formation and management for his various investments. He received a U.S. Congressman’s Medal of Merit from Ron Paul in 1985 and in 2000 he was named a Knight of the Legion of Honor by President Jacques Chirac. He is a member of the University of California at Santa Barbara Foundation Board of Trustees.

Manmeet Soni

Mr. Manmeet Soni is Chief Financial Officer, Executive Vice President - Finance, Chief Accounting Officer, Treasurer of Pharmacyclics Inc., effective August 16, 2013. He joined the Company in September 2012 as Corporate Controller and Executive Director of Finance and was appointed Vice President, Corporate Controller in February 2013. Mr. Soni is responsible for all Accounting, Treasury, Tax and SEC reporting functions in the Company. Previously, Mr. Soni worked at ZELTIQ Aesthetics Inc. from January 2012 to September 2012 where he served as a controller, Senior Director of Finance responsible for accounting, SEC and treasury functions. Prior to ZELTIQ, Mr. Soni worked with PricewaterhouseCoopers (PwC) from June 2007 to January 2012. Most recently he worked as Senior Manager in the Life Science and Venture Capital Group of the PwC San Jose office providing audit and advisory services to various public and privately held companies in the pharmaceutical, biotechnology, software and semiconductor space. He graduated from Hansraj College at Delhi University in India. He is also a Certified Public Accountant, licensed in the state of California and Chartered Accountant from India.

Mahkam Zanganeh

Dr. Mahkam Zanganeh, D.D.S., MBA., is the Chief Operating Officer of Pharmacyclics, Inc. Prior to being appointed Chief Operating Officer, Dr. Zanganeh served as the Company’s Chief of Staff and Chief Business Officer( Dec 2011-July 2012). Prior joining Pharmacyclics, Dr. Zanganeh served as President Director General (2007-2008) for the French government initiative bio-cluster project in France, establishing alliances and developing small life science business regionally. From September 2003 to August 2008, Dr. Zanganeh served as Vice President of Business Development for Robert W. Duggan & Associates. Dr. Zanganeh also served as worldwide Vice President of Training & Education (2002-2003) and President Director General for Europe, Middle East and Africa (1998 - 2002) for Computer Motion Inc., the world initiator of medical robotics. Dr. Zanganeh received a DDS degree from Louis Pasteur University in Strasbourg, France and MBA from Schiller International University in France.

Rainer Erdtmann

Mr. Rainer M. Erdtmann is Senior Vice President - Investor Relations and Administration of Pharmacyclics, Inc. He served as Vice President, Finance and Administration and Corporate Secretary from February 2009 to September 2012, was appointed Vice President, Investor Relations, Education and Training in September 2012 and was appointed Senior Vice President, Investor Relations and Administration in March 2013. Since 2002, he served as a managing director of Oxygen Investments, LLC, a manager of equity and real estate funds that he co-founded in December 2002. Since 1992, Mr. Erdtmann has served as managing director of United Properties Immobilien & Anlagen GmbH, a German based real estate development company, where he was originally responsible for building up the organization and overseeing its finance division. From 1998 to 2001, as well as in 2007 and 2008, Mr. Erdtmann worked with Robert W. Duggan & Associates, a private money management company, of which Robert W. Duggan, the Company’s Chairman and Chief Executive Officer, is principal. Mr. Erdtmann began his career in investment banking with Commerzbank in Frankfurt, Germany, and later joined Commerz International Capital Management as a portfolio manager for international clients. He graduated with distinction from the Westfaelische Wilhelms Universitaet in Muenster, majoring in finance and banking.

Urte Gayko

Dr. Urte Gayko, Ph.D., is Senior Vice President - Regulatory of Pharmacyclics Inc. She joined Pharmacyclics as Vice President, Regulatory Affairs in August 2012 and was appointed Senior Vice President, Regulatory in March 2013. From March 2008 to August 2012, Dr. Gayko served as Vice President of Regulatory and Clinical Affairs of Nodality Inc. From October 1999 to February 2008 she served as Director Global Regulatory Leader and Program Manager at Amgen Inc. Dr. Gayko received her B.S. and M.S. from Freie University Berlin, Germany and completed her Ph.D. research at Harvard University.

Sumita Ray

Ms. Sumita Ray is Chief Compliance Officer, Associate General Counsel - Healthcare Law of Pharmacyclics Inc., since April 2013. She has over 13 years of Legal, Regulatory and Compliance experience in the pharmaceutical and biotech industries. Sumita’s legal and compliance practice involves collaboration with the Clinical Development, Medical Affairs and Commercial business units, among others, on strategies to meet business goals in an ethical, legally sound and compliant manner. Prior to joining Pharmacyclics, she was at Elan Pharmaceuticals in San Francisco, where she was a member of the company’s Legal Leadership Team, and Head of the BioNeurology Law Group, and managing a team of lawyers and paralegals in global support of Elan’s pipeline and marketed products. In 2010, Sumita was significantly involved in the negotiation and settlement of Elan’s Corporate Integrity Agreement with the Office of Inspector General, and the subsequent drafting, implementing & training of the global business on key policies and procedures related to a Global Compliance program. Prior to joining Elan, Sumita was in the legal department of AstraZeneca Pharmaceuticals for 2.5 years, followed by Genentech for 3 years, where Sumita was the lead Legal Counsel for each respective company’s blockbuster drug product in Primary Care and Oncology, and engaged in several FDA label negotiations, approvals and subsequent product launches. Prior to moving in-house, Sumita spent 5 years as a pharmaceutical and products liability litigator at a Philadelphia based law firm, where she spent a amount of time on the FEN-PHEN products liability case, among other historic pharmaceutical cases. Sumita has a Juris Doctor, from Temple University Law School, and a Bachelor of Science in Microbiology, from the University of Arizona. She is licensed to practice law in Pennsylvania, New Jersey and California.

Gregory Hemmi

Dr. Gregory W. Hemmi, Ph.D., is Vice President - Chemical Operations of Pharmacyclics, Inc. Dr. Hemmi served as Senior Director, Chemical Development from January 2001 to April 2006 and as Director, Chemical Development from December 1997 to December 2000. Other positions held at Pharmacyclics include Group Leader, Chemical Development from May 1995 to November 1997 and Scientist from June 1992 to April 1995. After graduating with a B.S. in Chemistry, Dr. Hemmi received a Ph.D. in 1992 from the University of Texas at Austin under the direction of Professor Jonathan L. Sessler.

Darrin Beaupre

Betty Chang

Fong Clow

Dr. Fong Clow, D.Sc. is Vice President - Biostatistics, Programming, and Data Management of Pharmacyclics Inc. Dr. Clow joined Pharmacyclics first as a consultant in April 2011, then as Executive Director, Biometrics in August 2011 and was appointed Vice President, Biostatistics, Programming, and Data Management in September 2012. From February 2008 to September 2011, Dr. Clow was a consultant for various biotech and pharmaceutical companies. From June 2007 to January 2008 she served as managing Director at Morningside Technology Advisory, LLC, a private equity and venture capital firm. From March 2005 to May 2007, Dr. Clow served as Senior Vice President of Development at Novacea, Inc. Dr. Clow received a B.S. from Wuhan University in Wuhan, China. She received a M. Sc. and a D. Sc. from Harvard University of Public Health.

Elizabeth Faust

Dr. Elizabeth Faust, Ph.D., is Vice President - Medical Affairs of Pharmacyclics, Inc., since March 2013. Prior to Pharmacyclics, Dr. Faust served as Vice President, Clinical Science Research for Celgene from 2010 to 2013 where she led the oncology scientific field force. Prior to Celgene, from 2008 to 2010, she led Medical Affairs for Gloucester Pharmaceuticals, a privately-held company that gained FDA approval for Istodax. Gloucester Pharmaceuticals was acquired by Celgene in 2010. During her 12 years with Amgen (1995 to 2007), she was the Executive Director, Regional Medical Liaisons and built and led the Global Medical Writing Department. Dr. Faust received her Ph.D. in 1995 from UCLA under Dr. Owen Witte where she worked on genetic expression of progenitor B-cells and regulation of B-cell differentiation by stromal cells and holds the distinction of being the primary author on “Development of btk Transgenic Mice. Contemporary Topics in Micro and Immuno. 1995;194:363-369.”

Thorsten Graef

Dana Lee

Dr. Dana Lee, Pharm.D., is Vice President - Clinical Drug Safety of Pharmacyclics, Inc., since February 2013. Dr. Lee brings 23 years of experience in the pharmaceutical and healthcare industry with experience in both clinical safety and medical affairs. From 2011 to 2012, Dr. Lee was Vice President of Medical Affairs at Adventrx. From 2004 to 2011, Dr. Lee was Senior Director of Pharmacovigilance at Amylin Pharmaceuticals. Dr. Lee has participated in several launches with new molecular entities beginning with rituximab at Biogen-IDEC to exenatide at Amylin. Dr. Lee is a PharmD graduate from University of California, San Francisco.

Matthew Outten

Mr. Matthew D. Outten is Vice President - Commercial Operations of ., since February 2013. He also serves as Senior Director of the Market Access group, with responsibility for National Accounts, Trade and Distribution, Federal, Pricing and Contracting, Policy, and Advocacy. He was appointed Executive Director, Market Access in December 2013, and was appointed Vice President Commercial Operations in March 2014. In this role, Mr. Outten oversees all U.S. Sales, Marketing, and Market Access. Prior to joining Pharmacyclics, from July 2008 until February 2013, Mr. Outten held various roles of increasing responsibility in sales, marketing, and market access, most recently as Director of Managed Markets at Millennium: The Takeda Oncology Company. Mr. Outten graduated from Hamilton College and holds an MBA from The University of Delaware. He is also a certified professional coder from the American Acadamy of Professional Coders.

Scott Shearer

Dr. Scott Shearer, Ph.D., is Vice President - Global Quality of Pharmacyclics, Inc., since June 2012. From May 2009 to May 2012, Dr. Shearer served as Senior Director of Quality at Teikoku Pharma USA. From December 2007 to April 2009, he served as Senior Director of Quality and Analytical Chemistry at Cerimon Pharmaceuticals. From August 1999 to October 2007, Dr. Shearer held positions of increasing responsibility with various Johnson & Johnson pharmaceutical companies, most recently serving as Director of Analytical Chemistry. Dr. Shearer received a B.A. degree in Chemistry from Kenyon College and a Ph.D. in Analytical Chemistry from the University of Vermont.

Christophe Suchet

Mr. Christophe Suchet is Vice President - Information Technology of Pharmacyclics, Inc., since March 2013. Prior to joining Pharmacyclics, Mr. Suchet held various IT Senior leadership positions at Genentech from 2004 to 2013 including ERP, Enterprise, R&D and Commercial applications. He led organizations to define and implement IT strategies closely aligned with business drivers, demonstrated project management experience, and managed global and cross-functional teams. Prior to Genentech, he spent 2 years as IT senior manager at 3Com in charge of Enterprise, ERP and Sales applications. He also has 10 years of management consulting background working for KPMG Consulting and PricewaterhouseCoopers, involved primarily with ERP implementations for various industries. Mr. Suchet graduated from AgroParisTech, Paris with an MS is Economics and Biology.

Richard Love

Mr. Richard Love is General Counsel of Pharmacyclics Inc. Mr. Love joined Pharmacyclics as Vice President, Legal in June 2012, was appointed Secretary in September 2012 and was appointed Vice President, General Counsel in March 2013. From October 2008 to May 2012, he held several positions working for the IPSEN Group, most recently in the position of Vice-President, Head of Patents, U.S.A. From March 2007 to October 2008, he served as Vice-President, Intellectual Property & Licensing at Tercica, Inc. From October 2004 to March 2007, he served as Senior Director, Intellectual Property & Licensing at Tercica. From August 2001 to October 2004, he served as Senior Director, Intellectual Property at InterMune, Inc. Prior to InterMune, from May 1993 to August 2001, he served as Patent Counsel at Genentech, Inc. Mr. Love holds a J.D. from Golden Gate University School of Law and a B.A. in Mathematics from Hamilton College.

Shawn Cline Tomasello

Ms. Shawn Cline Tomasello is Chief Commercial Officer of the Company. Ms. Cline Tomasello is a 30-year industry veteran and former President of the Americas, Hematology and Oncology, for the Celgene Corporation, where she managed over $4 billion in revenue. Prior to joining Celgene, Ms. Cline Tomasello was the National Director of Hematology for Rituxan® at Genentech, where she was responsible for over $1.7 billion in revenue. Ms. Cline Tomasello had been with Celgene since 2005, where she was responsible for all aspects of commercial sales and marketing for six brands encompassing 11 indications. In addition, she was instrumental in strategic decision making regarding global expansion and M&A evaluations which led to the acquisition and integration of Pharmion Corporation, Gloucester Pharmaceuticals, Inc. and Abraxis Biosciences, Inc. Previously, Ms. Cline Tomasello was at Genentech for 16 years, where she was the National Director for Rituxan responsible for all in-line and new indications for the hematology commercial organization. At that time, Rituxan represented the majority of the company's corporate revenue. In addition, she held positions at Pfizer Laboratories, Miles Pharmaceuticals and Proctor & Gamble earlier in her career. Ms. Cline Tomasello received her B.S. in marketing from the University of Cincinnati and her M.B.A. from Murray State University, KY.

Maria Fardis

Dr. Maria Fardis, Ph.D., MBA, is Chief of Oncology Operations and Alliances of Pharmacyclics Inc. She joined Pharmacyclics as Vice President, Alliance and Global Project Management in December 2011, was appointed Executive Vice President, Alliances and Operations in September 2012 and was appointed Chief of Oncology Operations and Alliances in March 2013. Dr. Fardis joined Pharmacyclics in April 2011 as Senior Director of Global Project Management. Prior to joining the Company, from August 2001 to April 2012, Dr. Fardis held increasingly senior positions in Medicinal Chemistry and the project and portfolio management department at Gilead Sciences, Inc., most recently serving as Associate Director, Project and Portfolio Management. Dr. Fardis received her Ph.D. in Organic Chemistry from University of California Berkeley and her B.S. from the University of Illinois, Urbana- Champaign. Dr. Fardis holds an MBA from Golden Gate University.

Jesse McGreivy

Dr. Jesse McGreivy, M.D., has been appointed as Chief Medical Officer of Pharmacyclics, Inc., effective July 9, 2013. He served as Vice President - Clinical Science of the Company. From August 2006 to April 2012, Dr. McGreivy served as Clinical Research Medical Director at Amgen, Inc. From July 2005 to July 2006, he was Associate Clinical Director at Hoffman-LaRoche Inc. Dr. McGreivy received a B.A. from University of California, Berkeley and medical degree from The Ohio State University. He completed an internal medicine internship and residency at the Georgetown University Hospital and, subsequently, a hematology/oncology fellowship at the Lombardi Cancer Center at Georgetown University Hospital.

Heow Tan

Mr. Heow Tan is Chief of Technical Operations of Pharmacyclics, Inc. He joined Pharmacyclics in May 2012 as the Senior Vice President, Global Manufacturing and Technical Operations, was appointed Executive Vice President, Global Manufacturing, Technical Operations and Education in July 2012 and was appointed Chief of Technical Operations in March 2013. From November 2010 to May 2012, Mr. Tan served as Senior Vice President, Technical Operations of PreCision Dermatology (a spun off company of Collegium Pharmaceutical). From January 2009 to May 2012, Mr. Tan also served as Senior Vice President, Technical Operations of Collegium and from October 2006 he served as Vice President, Technical Operations of Collegium. From April 1998 to September 2006, Mr. Tan held increasingly senior positions at Prasecis Pharmaceuticals, Inc., most recently serving as Vice President, Industrial Operations (Manufacturing) & Development. Mr. Tan holds a M.S. in Engineering from the Ohio State University and a MBA from Santa Clara University.

Robert Booth

Dr. Robert F. Booth, Ph.D., serves as an Independent Director of Pharmacyclics, Inc., in December 2010. Dr. Booth is currently the Chief Executive Officer of Virobay, Inc., a drug discovery and development company. Dr. Booth was also the Executive Chairman of Virobay, Inc. from 2006 to 2010 and served concurrently as an Operating Partner and Senior Advisor at TPG Biotech, a venture capital company. From 2006 to 2007, Dr. Booth served as the acting Chief Scientific Officer of Galleon Pharmaceuticals, a company which is developing new therapeutics for diseases of the respiratory system. From 2002 to 2006, Dr. Booth was the Chief Scientific Officer at Celera Genomics. Dr. Booth was Senior Vice President at Roche Bioscience from 1989 to 2002, and was responsible for research and early development activities in the therapeutic areas of inflammation, autoimmunity, respiratory diseases, transplantation, bone diseases and viral diseases. Dr. Booth was a member of the Global Research Management Team and a member of the Business Development Committee, which oversaw licensing opportunities for Roche. During his time at Roche, Dr. Booth managed R&D organizations in both the United States and Europe. The Biology team for which Dr. Booth was responsible in the United Kingdom discovered and contributed to the development of saquinavir, the first HIV protease inhibitor to be launched. This achievement was recognized by the winning of the Prix Galien for Roche. Dr. Booth is currently Chairman of the Scientific Advisory Board and a Board Observer at Galleon Pharmaceuticals and a member of the Scientific Advisory Board of ShangPharma and Elcelyx Therapeutics. Dr. Booth is also an advisor to Glialogix Inc. and to the SPARK program at Stanford University. Dr. Booth received his Ph.D. and B.Sc. from the University of London in the field of biochemistry.

Kenneth Clark

Mr. Kenneth A. Clark is Independent Director of Pharmacyclics, Inc., since November 2012. Mr. Clark has been a member of the law firm Wilson Sonsini Goodrich & Rosati, PC, since 1993, and currently serves as a member of its Board of Directors. His practice has focused on strategic transactions in the biopharmaceutical industry for over 25 years, and has included several of partnering transactions in the industry over that period. He holds a B.A. degree from Vanderbilt University and a law degree from the University of Texas at Austin.

Eric Halvorson

Mr. Eric H. Halvorson is Independent Director of Pharmacyclics Inc., since December 2011. Mr. Halvorson is engaged in the practice of law and has been Of Counsel to the law firm of Stowell, Zeilenga, Ruth, Vaughn & Treiger, LLP since 2010. Mr. Halvorson was President and Chief Operating Officer of Salem Communications Corporation from 2007 to 2008. He was Executive Vice President and Chief Operating Officer of Salem Communications Corporation from 1995 to 2000. Prior to becoming Chief Operating Officer, he was the company’s Vice President and General Counsel for ten years. Mr. Halvorson was a member of the Board of Directors of Salem Communications Corporation from 1988 to 2008. He has been a member of the Board of Directors of Intuitive Surgical, Inc. since 2003. From 2000-2003, 2005-2007 and 2009-2011, Mr. Halvorson was Executive in Residence at Pepperdine University and Adjunct Professor of Law at Pepperdine Law School. From 2003-2005, Mr. Halvorson served as President and Chief Executive Officer of The Thomas Kinkade Company. He was a partner at Godfrey & Kahn, a law firm based in Milwaukee, Wisconsin, from 1976-1985. Mr. Halvorson holds a B.S. in Accounting from Bob Jones University and a J.D. from Duke University School of Law.

Minesh Mehta

Dr. Minesh P. Mehta, M.D., serves as Independent Director of Pharmacyclics, Inc., in September 2008. Dr. Mehta is internationally recognized with respect to human clinical drug trial strategy, design and execution and has managed national and international trials of all sizes including International Phase 3 trials. He was Professor in the Department of Human Oncology at the University of Wisconsin’s School of Medicine and Public Health from 2002-2010, including being the Program Leader of the Imaging and Radiation Sciences Program of the Paul P. Carbone Comprehensive Cancer Center (UWCCC). Dr. Mehta was Chairman of the Department of Human Oncology from 1997 to 2007. From 2010-2012, he served as Professor of Radiation Oncology at Northwestern University in Chicago. Currently (since October 2012), he is Professor of Radiation Oncology at University of Maryland, and Director of the Maryland Proton Treatment Center in Baltimore, Maryland. He has been a member of the Board of Directors of the American Society for Therapeutic Radiology and Oncology (ASTRO) since 2006 and Chair of the Radiation Therapy Oncology Group (RTOG) Brain Tumor Committee since 1998. From 1997 to 2001, he served as an ad-hoc member of the FDA’s Technology Assessment Committee and from 2001 to 2005, he served on and eventually Chaired the FDA Radiological Devices Panel. Dr. Mehta obtained his medical degree at the University of Zambia in 1981 and commenced his residency there at the Ndola Central Hospital. He moved to the University of Wisconsin, Madison, in 1984 and completed his residency in radiation oncology in 1988 when he took up an Assistant Professorship in Human Oncology, was promoted to Associate Professor and became the Director of the Radiation Oncology Residency Training Program. After serving as Vice-Chairman and Interim Chairman, Dr. Mehta became Chair of Human Oncology and also a Professor in the Department of Neurological Surgery.

David Smith

Dr. David Duane Smith, Ph.D., is an Independent Director of Pharmacyclics, Inc., in October 2008. Dr. Smith is a professor of biostatistics at City of Hope, a cancer research hospital in Los Angeles and holds a B.A. in Mathematics and a Ph.D. in Statistics. After his dissertation on integrating and synthesizing information in clinical and observational studies in oncology, he served as a Biostatistical Reviewer for the Division of Oncology Drug Products, U.S. Food and Drug Administration (FDA) for 3 years. During his tenure at the FDA, he reviewed more than 40 chemotherapy INDs and NDAs. He represented the FDA statistical perspective at five Oncologic Drugs Advisory Committee sessions, including three on the problems of missing data in outcomes research. After leaving the FDA in 2000, he went to City of Hope and the front lines of cancer research. While at City of Hope, he has designed and analyzed over 50 solid tumor and hematology protocols at all levels of development, from pre-clinical and marker discovery studies to Phase II/III trials. Dr. Smith has been a co-investigator on grants from the National Cancer Institute, National Institutes of Health, the American Cancer Society, the Susan G. Komen Breast Cancer Foundation and the Leukemia-Lymphoma Society.

Richard Van den Broek

Mr. Richard A. Van Den Broek serves as Independent Director of Pharmacyclics, Inc., in December 2009. Since 2004, Mr. van den Broek has been Managing Partner of HSMR Advisors, LLC, an investment fund focused on the biotechnology industry. From 2000 through 2003 he was a Partner at Cooper Hill Partners, LLC, an investment fund focused on the healthcare sector. Prior to that Mr. van den Broek had a ten year career as a biotech analyst, starting at Oppenheimer & Co., then Merrill Lynch, and finally at Hambrecht & Quist. Mr. van den Broek is a Director and member of the Strategy Committee of Strategic Diagnostics, Inc. and is a Director and member of the Remuneration Committee of Pharmaxis, Ltd., which is an Australia listed company. He is a graduate of Harvard University and is a Chartered Financial Analyst.
Search Stocks